Pacific Edge, a cancer diagnostics company based in Dunedin, New Zealand, has announced an update to its billing policies in the US for Cxbladder tests.
The new process requires all patients not covered by a contracted health insurer to be informed of their responsibility when ordering the test, and encourages them to complete a Patient Assist form.
This follows the finalization of a Local Coverage Determination (LCD) that could see Medicare coverage of Cxbladder tests cease on 17 July 2023.
Pacific Edge Chief Executive Dr Peter Meintjes hopes the new approach will improve collections in the event of denial from any non-contracted insurer, including Medicare.
See more
